Carenostics Revenue and Competitors
Employee Data
- Carenostics has 16 Employees.
- Carenostics grew their employee count by 129% last year.
Carenostics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | Co-Founder and COO | Reveal Email/Phone |
3 | Co-Founder & Chief Operating Officer | Reveal Email/Phone |
Carenostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $35M | 59 | 7% | N/A | N/A |
#2 | $3.5M | 105 | 17% | N/A | N/A |
#3 | N/A | 27 | 35% | N/A | N/A |
#4 | N/A | 24 | 33% | N/A | N/A |
#5 | N/A | 5 | 0% | N/A | N/A |
#6 | $7.5M | 102 | 17% | N/A | N/A |
#7 | $7.5M | 72 | 44% | N/A | N/A |
#8 | $750M | 77 | 3% | N/A | N/A |
#9 | N/A | 14 | 75% | N/A | N/A |
#10 | $15M | 94 | 45% | N/A | N/A |
What Is Carenostics?
Carenostics develops healthcare AI solutions to identify opportunities for earlier clinical intervention with chronic disease patients. We learn machine learning models from patient data collected in routine care, and integrate directly into provider EHRs to help physicians identify patients with undiagnosed chronic disease, project their decline over time, and match them to guideline / evidence-based treatment. Carenostics partners with leading providers, payers, pharma companies, care management companies, academics, and government agencies to address the gaps in chronic disease care. Our flagship solution, CKDx, is a clinical decision support tool developed with the goal of eradicating undiagnosed chronic kidney disease while reducing the disparities in care faced by minority populations.
keywords:N/AN/A
Total Funding
16
Number of Employees
N/A
Revenue (est)
129%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 16 | 7% | N/A |
#2 | $2.4M | 16 | -6% | N/A |
#3 | $2.6M | 16 | -11% | N/A |
#4 | $2.4M | 16 | 14% | N/A |
#5 | $2.2M | 16 | -36% | N/A |